University Cancer Center Leipzig (UCCL), University Hospital Leipzig, Leipzig, Germany,
1st Department of Medicine, University Hospital Leipzig, Leipzig, Germany,
Oncol Res Treat. 2019;42(6):350-353. doi: 10.1159/000497216. Epub 2019 Apr 17.
Some chemotherapy formulations contain ethanol as a solvent which can become relevant for medical and nonmedical reasons. Only a few studies have tried to quantify the effects of ethanol in chemotherapy preparations. Furthermore, the alcohol amount highly depends on the specific formulation, with some variation among different manufacturers. Although the actual increase in blood alcohol levels after ethanol-based chemotherapies seems to be limited, the FDA recently released a warning that docetaxel may cause symptoms of alcohol intoxication. Here, we report on a patient with breast cancer who experienced a relapse of alcohol abuse after a single docetaxel infusion. We hypothesize a causal relationship with the ethanol-containing docetaxel infusion. Today, no guidelines exist for the use of ethanol-based chemotherapy, and patient consent forms do not address this matter. We conclude that physicians prescribing chemotherapy and patients should be aware of the potential risks of ethanol-containing infusions and nonethanol-based alternatives should be discussed when needed or desired by the patient. This could be facilitated by revised patient consent forms.
一些化疗制剂含有乙醇作为溶剂,这可能与医疗和非医疗原因有关。只有少数研究试图量化乙醇在化疗制剂中的作用。此外,酒精含量高度取决于特定的配方,不同制造商之间存在一些差异。尽管基于乙醇的化疗后血液中酒精水平的实际升高似乎有限,但 FDA 最近发布警告称,多西他赛可能会引起酒精中毒症状。在这里,我们报告了一名乳腺癌患者在单次多西他赛输注后出现酒精滥用复发的情况。我们假设这与含有乙醇的多西他赛输注有关。目前,尚无关于使用乙醇化疗的指南,患者同意书也没有涉及这一问题。我们得出结论,开具化疗药物的医生和患者都应该意识到含有乙醇的输注的潜在风险,并且在患者需要或希望时,应该讨论使用非乙醇基替代物。修订后的患者同意书可以为此提供便利。